Biofrontera Inc. has taken a significant step by removing its warrants from trading on the Nasdaq Stock Market. This decision, filed on October 30, 2026, under the 25-NSE form, is expected to have implications for the company and its stakeholders.

Background

Biofrontera Inc. operates in the Pharmaceutical Preparations sector, as classified under SIC 2834. The company is listed on the Nasdaq under the tickers BFRI and BFRIW. As an emerging growth company, Biofrontera is focused on developing and commercializing innovative dermatological products. Recent filings include an 8-K on September 14, 2026, and a 10-Q on August 13, 2026.

What the Filing Says

The filing states that the company has notified the removal of its warrants from trading, effective as of the filing date. The notification was signed by Tara Petta, Assistant Vice President at Nasdaq, indicating that the decision aligns with regulatory provisions.

Impact

This removal may affect investors holding the warrants, as they will no longer be able to trade them on the Nasdaq. It also signals a potential shift in Biofrontera's financial strategy, which could influence investor confidence and market perception.

What's Next

The filing does not specify what happens next for Biofrontera Inc. following this removal.

Company Information

Biofrontera Inc. is incorporated in Delaware and operates out of Woburn, Massachusetts. The company’s fiscal year ends on December 31. The company is classified under the Pharmaceutical Preparations sector, specifically SIC 2834, indicating its focus on the development and commercialization of pharmaceutical products.

Regulatory Context

The removal of the warrants from trading was executed in accordance with the regulatory provisions outlined in 17 CFR 240.12d2-2(a)(2). This regulation governs the conditions under which securities can be removed from trading on national exchanges, indicating that the decision was made following established legal frameworks.

Contact Information

For further inquiries, Biofrontera Inc. can be reached at their business address: 120 Presidential Way, Suite 330, Woburn, MA 01801, or by phone at 781-245-1325.

Absence of Future Plans

The filing does not provide any information regarding future plans or strategies that Biofrontera Inc. may pursue following the removal of the warrants. There is no indication of potential new offerings or changes in corporate governance that may arise as a result of this decision.